SCHEMBL4306735

SCHEMBL4306735

Cc1ccc(CN(c2ccccc2)C2CCN(C(=O)OC(C)(C)C)CC2)cc1

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.57
MEN1 O00255 4/20 0.57
PTPRB P23467 1/20 0.54
PTPN11 Q06124 1/20 0.54
GPR119 Q8TDV5 5/20 0.53
JAK2 O60674 1/20 0.53
JAK1 P23458 1/20 0.53
TP53 P04637 1/20 0.51
CCR5 P51681 1/20 0.48
KCNH2 Q12809 1/20 0.48
STS P08842 1/20 0.48
KDM4E B2RXH2 1/20 0.48
PKM P14618 1/20 0.48
USP30 Q70CQ3 1/20 0.47
TDP1 Q9NUW8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4307698 0.89 KMT2A (0.58) KMT2AMEN1PTPRBPTPN11GPR119
SCHEMBL4311345 0.89 KMT2A (0.58) KMT2AMEN1GPR119JAK2JAK1
SCHEMBL4307751 0.89 KMT2A (0.58) KMT2AMEN1GPR119JAK2JAK1
SCHEMBL4306235 0.89 MEN1 (0.53) KMT2AMEN1PTPRBPTPN11GPR119
SCHEMBL4557100 0.89 KMT2A (0.50) KMT2AMEN1PTPRBPTPN11GPR119
SCHEMBL4303459 0.88 GPR119 (0.51) KMT2AMEN1GPR119JAK2JAK1
SCHEMBL5969496 0.86 CCR5 (0.53) CCR5KCNH2
SCHEMBL4309350 0.86 MEN1 (0.67) KMT2AMEN1PTPRBPTPN11GPR119
SCHEMBL4318763 0.85 MEN1 (0.53) KMT2AMEN1PTPRBPTPN11GPR119
SCHEMBL4302400 0.85 MEN1 (0.53) KMT2AMEN1PTPRBPTPN11GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1556045-B1 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS UCB SA (BE) 2006-08-02 EP claimed
US-20060128753-A1 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments UCB, S.A. (BE) 2006-06-15 US claimed
US-7488741-B2 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments UCB PHARMA, S.A. (BE) 2009-02-10 US disclosed
EP-1693061-A1 Use of 4-aminoderivatives for the preparation of a medicament for treating neurological diseases UCB, S.A. (BE) 2006-08-23 EP disclosed
EP-1556045-B1 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS UCB SA (BE) 2006-08-02 EP disclosed
US-20060128753-A1 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments UCB, S.A. (BE) 2006-06-15 US disclosed
EP-1556045-A1 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS UCB, S.A. (BE) 2005-07-27 EP disclosed
WO-2004030668-A1 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS UCB, S.A. (BE) 2004-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128753-A1 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments PNMT, HTR5A, HTR4 KMT2A 1360/4885MEN1 4456/4885PTPRB 1722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.